Primary prevention of patients with high LDL-cholesterol levels greater than 4.9 mmol/l: analysis from the WOSCOPS trial

28 August 2016 (14:15 - 14:30)

Organised by:

About the speaker

Doctor Antonio J Vallejo-Vaz

University of Seville, Seville (Spain)

5 More presentations in this session

Presentation thumbnail

The influence of blinding and un-blinding on statin related adverse events (AEs): new evidence from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Associate Professor A. Gupta (London, GB)

Presentation thumbnail

Lipid Levels and CV Outcome with CETP Inhibition by Evacetrapib in the ACCELERATE Trial

Professor A. Lincoff (Cleveland, US)

Presentation thumbnail

The Benefit of Adding Ezetimibe to Statin Therapy in Patients With or Without prior Coronary Artery Bypass Graft surgery in the IMPROVE-IT Trial

Professor A. Eisen (Petah Tikva, IL)

Presentation thumbnail

First-in-man study of a pacemaker-mediated programmable hypertension control therapy

Professor P. Neuzil (Prague, CZ)

Presentation thumbnail

The relationship between severe hypoglycaemic events and cardiovascular outcomes is bidirectional: novel results from TECOS

Professor E. Standl (Munich, DE)

Access the full session

Session thumbnail

Clinical Trial Update Prevention

The Event

ESC Congress 2016

28 August 2016 14:15 CET

You may be interested in

Congress Presentation

A collaborative working project in primary care: optimising lipid lowering therapies for secondary prevention in high risk patients

4 April 2025

Congress Presentation

NATURE-LEGACY: Long term legacy benefit of Lowering LDL and SBP

1 September 2025

Congress Presentation

Statins for primary prevention among elderly men and women.

27 August 2021

Webinar

Risk assessment and lipid management in primary prevention

11 April 2024

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources